Sanofi / Regeneron Clinical Trial Pipeline: 174 Active Trials, 83 Changes This Month

58 trials changed in the last 30 days: 2 stopped, 8 with notable changes, 48 with minor changes only.

Stopped

SPECIFI-CD · SAR441566 · Crohn's Disease

Trial terminated

Sponsor's reason: Business decision.

Also in this update: Final enrollment: 105 participants (planned 260)

SanofiPhase 2 NCT06637631 Registry history of NCT06637631 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Stopped

RIVER-ASTHMA · Subcutaneous Amlitelimab · Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

Trial terminated

Sponsor's reason: Sponsor decision; the decision is not related to any safety concern.

SanofiPhase 2 NCT06033833 Registry history of NCT06033833 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Notable

Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

Primary endpoint(s) modified

And 1 more change in the last 30 days

SanofiPhase 1/2 NCT07734649 Registry history of NCT07734649 on ClinicalTrials.gov (opens the registry)

Updated Oct 14, 2026
Notable

Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19

Recruitment opened

Also in this update: Trial sites expanded: 0 → 20 locations; Start date changed from estimate of Oct 2, 2026 to Oct 1, 2026

SanofiPhase 4 NCT07861542 Registry history of NCT07861542 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Notable

Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne

Sponsor changed: Sanofi Pasteur, a Sanofi Company to Sanofi

SanofiPhase 2 NCT07756957 Registry history of NCT07756957 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Notable

COLOSSUS · Lunsekimig · Chronic Obstructive Pulmonary Disease (COPD)

Recruitment opened

Also in this update: Trial sites expanded: 0 → 3 locations; Start date changed from estimate of Sep 14, 2026 to Sep 16, 2026

SanofiPhase 3 NCT07793409 Registry history of NCT07793409 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Notable

Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older

Recruitment opened

Also in this update: Trial sites expanded: 0 → 16 locations; Start date changed from estimate of Sep 7, 2026 to Sep 9, 2026

SanofiPhase 2 NCT07810010 Registry history of NCT07810010 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026
Notable

AERIFY-1 · SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Results posted: Oct 15, 2026

SanofiPhase 3 NCT04701983 Registry history of NCT04701983 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Notable

AERIFY-2 · SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Results posted: Oct 9, 2026

SanofiPhase 3 NCT04751487 Registry history of NCT04751487 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Notable

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) · Non-cystic Fibrosis Bronchiectasis

Results posted: Oct 7, 2026

SanofiPhase 2 NCT06280391 Registry history of NCT06280391 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026

Show 48 trials with minor changes only

Minor

RSV Immunisation Status in Queensland (Australia)

Trial completed

And 2 more changes in the last 30 days

SanofiNot specified NCT07615192 Registry history of NCT07615192 on ClinicalTrials.gov (opens the registry)

Updated Oct 14, 2026
Minor

LUNA 3 · Rilzabrutinib in Adults and · Persistent or Chronic Immune Thrombocytopenia (ITP)

Trial completed

Principia Biopharma, a Sanofi CompanyPhase 3 NCT04562766 Registry history of NCT04562766 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026
Minor

Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data

Trial completed

Also in this update: Final enrollment: 4878935 participants (planned 533000); and 2 more changes in the last 30 days

SanofiNot specified NCT07094373 Registry history of NCT07094373 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

Control Study of the Safety and Immunogenicity of vYF in Pediatric Population

Primary completion pushed from Aug 8, 2026 to Nov 28, 2026

SanofiPhase 3 NCT07103148 Registry history of NCT07103148 on ClinicalTrials.gov (opens the registry)

Updated Oct 14, 2026
Minor

ATLAS-OLE · Fitusiran · Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

Trial completed

Also in this update: Primary completion date changed from estimate of Nov 5, 2026 to Sep 14, 2026

Genzyme, a Sanofi CompanyPhase 3 NCT03754790 Registry history of NCT03754790 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

AERIFY-4 · Itepekimab · COPD

Trial completed

Also in this update: Primary completion date changed from estimate of Dec 1, 2026 to Sep 10, 2026

SanofiPhase 3 NCT06208306 Registry history of NCT06208306 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Minor

COLOR UC · Brivekimig · Ulcerative Colitis

Enrollment closed, study ongoing

SanofiPhase 2 NCT06975722 Registry history of NCT06975722 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

PETITE-T1D · Teplizumab in Pediatric Stage 2 Type 1 Diabetes

Trial completed

Also in this update: Final enrollment: 23 participants (planned 20)

SanofiPhase 4 NCT05757713 Registry history of NCT05757713 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026
Minor

GLOBOSPIN · Real-World Effectiveness of Dupilumab · Prurigo Nodularis: An Observational Study

Trial completed

Also in this update: Final enrollment: 110 participants (planned 100)

SanofiNot specified NCT05991323 Registry history of NCT05991323 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

FRAME · French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

Enrollment closed, study ongoing

SanofiNot specified NCT06837454 Registry history of NCT06837454 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

PROTECT-ALT · Impact of Efanesoctocog Alfa on Long-term Joint Health · Hemophilia A in Taiwan

Enrollment closed, study ongoing

Also in this update: Final enrollment: 79 participants (planned 100)

SanofiNot specified NCT06684314 Registry history of NCT06684314 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

PROTYPE2 · Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

Enrollment closed, study ongoing

Also in this update: Final enrollment: 572 participants (planned 900)

SanofiNot specified NCT06039241 Registry history of NCT06039241 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026
Minor

Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease · IVS4 Mutation in Taiwan

Primary and study completion pushed from Sep 10, 2026 to Nov 6, 2026

SanofiNot specified NCT06052800 Registry history of NCT06052800 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

Rilzabrutinib · Graves' Disease

Primary completion pushed from Aug 25, 2026 to Feb 11, 2027

Also in this update: Trial sites expanded: 15 → 24 locations; Study completion pushed from Sep 23, 2026 to Mar 11, 2027

SanofiPhase 2 NCT06984627 Registry history of NCT06984627 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

LIBRA · Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

Trial sites expanded: 53 → 63 locations

SanofiPhase 3 NCT06975865 Registry history of NCT06975865 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Minor

βETA PRESERVE · Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Trial sites expanded: 197 → 202 locations

SanofiPhase 3 NCT07088068 Registry history of NCT07088068 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

FREXERA · Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Trial sites expanded: 63 → 73 locations

And 1 more change in the last 30 days

SanofiPhase 2/3 NCT07412470 Registry history of NCT07412470 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

PERIDOT · Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Trial sites reduced: 58 → 50 locations

SanofiPhase 3 NCT05206773 Registry history of NCT05206773 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

CEREN-3 · Itepekimab · Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

Trial sites expanded: 23 → 46 locations

SanofiPhase 3 NCT07424144 Registry history of NCT07424144 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

Frexcite · Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration · Multiple Sclerosis

Trial sites expanded: 40 → 68 locations

SanofiPhase 3 NCT07325292 Registry history of NCT07325292 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

AQUA · Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Trial sites expanded: 150 → 154 locations

SanofiPhase 3 NCT06241118 Registry history of NCT06241118 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

BRIGHTEN · Brivekimig · Moderate to Severe Hidradenitis Suppurativa

Trial sites expanded: 79 → 85 locations

SanofiPhase 2 NCT07170917 Registry history of NCT07170917 on ClinicalTrials.gov (opens the registry)

Updated Oct 14, 2026
Minor

OPALS · Sarilumab · RA

Trial sites expanded: 4 → 12 locations

SanofiPhase 1/2 NCT07704580 Registry history of NCT07704580 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

STRIDE · Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

Trial sites expanded: 3 → 7 locations

SanofiNot specified NCT07612878 Registry history of NCT07612878 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Minor

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

Trial sites expanded: 19 → 25 locations

SanofiPhase 3 NCT07348692 Registry history of NCT07348692 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026
Minor

AIRITY · Disease Characteristics and Outcomes · Asthma in Routine Clinical Practice

Trial sites expanded: 62 → 71 locations

SanofiNot specified NCT07556159 Registry history of NCT07556159 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor

THESEUS · Lunsekimig Compared With Placebo · Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Trial sites expanded: 214 → 315 locations

SanofiPhase 3 NCT07190222 Registry history of NCT07190222 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

ROCKaspire · How Effective Belumosudil Tablets Are for Treating Adult · Chronic Lung Allograft Dysfunction

Trial sites expanded: 79 → 82 locations

SanofiPhase 3 NCT06082037 Registry history of NCT06082037 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Minor

STARSCAPE-1 · Induction Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease

Trial sites expanded: 301 → 432 locations

SanofiPhase 3 NCT07184931 Registry history of NCT07184931 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Minor

RILIEF · 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo · IgG4-related Disease

Trial sites expanded: 79 → 92 locations

SanofiPhase 3 NCT07190196 Registry history of NCT07190196 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Minor

STARSCAPE-2 · Maintenance Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease

Trial sites expanded: 35 → 90 locations

SanofiPhase 3 NCT07184944 Registry history of NCT07184944 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Minor

PERSEPHONE · Lunsekimig Compared With Placebo · Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Trial sites expanded: 221 → 294 locations

SanofiPhase 3 NCT07190209 Registry history of NCT07190209 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

LUMINA 3 · Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

Trial sites expanded: 95 → 99 locations

SanofiPhase 3 NCT07086976 Registry history of NCT07086976 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

LTS · Riliprubart · CIDP

Trial sites expanded: 49 → 59 locations

SanofiPhase 3 NCT06859099 Registry history of NCT06859099 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Minor

SKYPS · Repeated Dose-finding Study of Sarilumab in Children and · Systemic Juvenile Idiopathic Arthritis (SKYPS)

Trial sites expanded: 32 → 37 locations

SanofiPhase 2 NCT02991469 Registry history of NCT02991469 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Minor

RESULT · Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Trial sites expanded: 71 → 75 locations

SanofiPhase 2 NCT06500702 Registry history of NCT06500702 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Minor

TREMHANCE · SAR448851 · Early Alzheimer's Disease

Trial sites expanded: 1 → 11 locations

SanofiPhase 2 NCT07688213 Registry history of NCT07688213 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

CLAROS · SAR445399 · Moderate to Severe Hidradenitis Suppurativa

Trial sites expanded: 67 → 83 locations

SanofiPhase 2 NCT07225569 Registry history of NCT07225569 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

Sarilumab Efficacy and Safety · Early Polymyalgia Rheumatica

Trial sites expanded: 14 → 74 locations

SanofiPhase 4 NCT07286214 Registry history of NCT07286214 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

AIRLYMPUS · Lunsekimig (SAR443765) Compared With Placebo · High-risk Asthma

Trial sites reduced: 230 → 221 locations

SanofiPhase 2 NCT06676319 Registry history of NCT06676319 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

AEOLUS · Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease

Trial sites expanded: 68 → 82 locations

SanofiPhase 4 NCT07053423 Registry history of NCT07053423 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

Balinatunfib · Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)

Trial sites expanded: 2 → 10 locations

SanofiPhase 2 NCT07222189 Registry history of NCT07222189 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

AIRPHRODITE · Lunsekimig (SAR443765) · Asthma

Trial sites expanded: 127 → 150 locations

SanofiPhase 2 NCT06609239 Registry history of NCT06609239 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

One-time Intravitreal Injection of SAR446597 · Geographic Atrophy Secondary to Age-related Macular Degeneration

Trial sites expanded: 18 → 30 locations

SanofiPhase 1/2 NCT07215234 Registry history of NCT07215234 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Minor

CHROMA CD · Brivekimig · Crohn's Disease

Interventions modified

SanofiPhase 2 NCT06958536 Registry history of NCT06958536 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Minor

ARMADA-AD · This Study is a Non-interventional Disease Registry of Adolescent and Adult · Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Trial sites expanded: 79 → 82 locations

SanofiNot specified NCT07290803 Registry history of NCT07290803 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026
Minor

AURORA · Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes

Trial sites expanded: 22 → 28 locations

SanofiNot specified NCT07380711 Registry history of NCT07380711 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

ProMEAL · Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab · Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany

Trial sites expanded: 1 → 15 locations

SanofiNot specified NCT06695897 Registry history of NCT06695897 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

First posted	Trial	Phase	Status
2026-10-06	NCT07861542 Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at…	Phase 4	Recruiting
2026-10-02	NCT07855250 An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1…	Phase 1	Recruiting
2026-10-01	NCT07853131 Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult…	Phase 1	Not Yet Recruiting

NCT ID	Title	Condition	Status	Updated
Phase 4
NCT06941870	Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy	Factor VIII Deficiency	Recruiting	2026-10-15
NCT07861542	Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at…	COVID-19	Recruiting	2026-10-15
NCT06145373	A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe…	Hemophilia A	Recruiting	2026-09-23
NCT07053423	A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants…	Chronic Obstructive Pulmonary Disease	Recruiting	2026-09-22
NCT07286214	Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica	Polymyalgia Rheumatica	Recruiting	2026-09-22
NCT06666413	China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With…	Glycogen Storage Disease Type II	Recruiting	2026-03-23
NCT06671587	iGlarLixi CGM Study in Chinese T2D Individuals After OADs	Type 2 Diabetes (T2D)	Recruiting	2026-03-17
NCT06101095	A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo…	Eosinophilic Oesophagitis	Active, Not Recruiting	2026-09-30
NCT05164055	Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA…	Glycogen Storage Disease Type II	Active, Not Recruiting	2026-09-09
NCT07135973	A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above…	Chronic Graft Versus Host Disease	Not Yet Recruiting	2026-05-12
NCT05097287	Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline…	Asthma	Active, Not Recruiting	2026-04-16
NCT05983068	A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric…	Dermatitis Atopic	Active, Not Recruiting	2026-04-13
NCT07109297	Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in…	RSV Immunization	Active, Not Recruiting	2026-03-23
Phase 3
NCT05263206	Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants…	Pruritus	Recruiting	2026-10-15
NCT06975865	The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With…	Sickle Cell Disease	Recruiting	2026-10-15
NCT07103148	A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population	Yellow Fever Immunization	Recruiting	2026-10-14
NCT06293053	A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6…	Prurigo Nodularis	Recruiting	2026-10-13
NCT07088068	A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in…	Type 1 Diabetes Mellitus	Recruiting	2026-10-13
NCT07325292	Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous…	Multiple Sclerosis	Recruiting	2026-10-13
NCT07348692	Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy…	Pneumococcal Immunization	Recruiting	2026-10-05
NCT07190222	Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult…	Chronic Obstructive Pulmonary Disease	Recruiting	2026-10-01
NCT06082037	A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants…	Lung Transplant Rejection	Recruiting	2026-09-23
NCT07184931	An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants…	Crohn's Disease	Recruiting	2026-09-23
NCT07184944	A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants…	Crohn's Disease	Recruiting	2026-09-23
NCT07190196	A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults…	Immunoglobulin G4 Related Disease	Recruiting	2026-09-23

Sanofi / Regeneron clinical trial pipeline

What changed in the last 30 days

New trial filings, last 30 days

Active trials by phase

Active trials top 25 of 174

Disease areas by active trials, top 10 of 20